 MannKind Corp NASDAQ: MNKD is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application for Tyvaso DPI. The FDA declined to approve the New Drug Application, citing a deficiency related to an open inspection issue at a third-party analytical testing center for treprostinil drug substance, the active ingredient of Tyvaso DPI. 